GBT021601

DRUG5 trials

Sponsors

Global Blood Therapeutics Inc., Pfizer

Conditions

Renal ImpairmentSickle Cell Disease

Phase 1

A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)

CompletedNCT04983264

PfizerSickle Cell Disease

Start: 2021-05-21End: 2022-12-06Updated: 2024-06-10

A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants

CompletedNCT05036512

PfizerSickle Cell Disease

Start: 2020-12-09End: 2023-02-07Updated: 2023-07-25

A GBT021601 ADME Microtracer Study in Healthy Volunteers

CompletedNCT05718687

PfizerSickle Cell Disease

Start: 2022-12-22End: 2023-08-10Updated: 2025-01-08

Study of GBT021601 in Participants With Renal Impairment

TerminatedNCT05878704

PfizerRenal Impairment

Start: 2023-06-29End: 2024-07-29Updated: 2024-10-15

Phase 2

C5351004 - A Phase 2/3 Randomized, Multicenter Study of Osivelotor Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell Disease

SuspendedCTIS2023-508766-14-00

Global Blood Therapeutics Inc.Sickle Cell Disease

Target: 20Updated: 2024-07-25

Related Papers

A Phase 1 Microtracer Study Evaluating the Mass Balance, Excretion, and Pharmacokinetics of Osivelotor in Healthy Participants

Clinical and Translational Science2026-05-25